Skip to main content
Top
Published in: Drug Safety 8/2014

01-08-2014 | Original Research Article

Undesirable Effects Related to Oral Antineoplastic Drugs: Comparison Between Patients’ Internet Narratives and a National Pharmacovigilance Database

Authors: Arnaud Pages, Emmanuelle Bondon-Guitton, Jean Louis Montastruc, Haleh Bagheri

Published in: Drug Safety | Issue 8/2014

Login to get access

Abstract

Background

The Internet is changing the way people learn about health and illness. Over the previous decade, the oral antineoplastic (OAN) agents have changed patient management allowing more ambulatory care. In this regard, websites could be an interesting source of data about OAN-induced adverse events (AEs).

Objective

The aim of the study was to describe the characteristics of AEs, as reported on websites by patients exposed to OAN agents, and to compare these to those recorded in the French pharmacovigilance database (FPVD).

Methods

We performed a retrospective study to collect AEs reported by patients in five of the best-known website forums in France over 1 year (2011). For each report, we recorded demographic data, cancer type, drug involved and AEs. The same analysis was done in the FPVD for OAN-induced adverse drug reactions (ADRs).

Results

A total of 202 AEs were identified in website posts and 1,448 ADRs were found in the FPVD. The most cited drugs in websites were protein kinase inhibitors (n = 88, 43.5 %) and hormone antagonists (n = 61, 30.2 %). More musculoskeletal disorder reports were found in the patient websites compared with the FPVD (16.34 vs. 4.70 %, p < 0.001). As for skin disorders, we collected fewer reports in the patient website forums than in the FPVD (13.37 vs. 22.17 %, p = 0.004). AEs reported in the patient websites were less serious (n = 10, 4.95 %) than ADRs recorded in the FPVD (n = 999, 68.99 %) (p < 0.001).

Conclusions

AEs reported in the website forums are considered by patients to be relevant enough to be shared. Data from patient websites could be used as a source of data to detect AEs alongside conventional pharmacovigilance.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bartlett YK, Coulson NS. An investigation into the empowerment effects of using online support groups and how this affects health professional/patient communication. Patient Educ Couns. 2011;83:113–9.PubMedCrossRef Bartlett YK, Coulson NS. An investigation into the empowerment effects of using online support groups and how this affects health professional/patient communication. Patient Educ Couns. 2011;83:113–9.PubMedCrossRef
2.
go back to reference Armstrong N, Powell J. Patient perspectives on health advice posted on Internet discussion boards: a qualitative study. Health Expect. 2009;12:313–20.PubMedCrossRef Armstrong N, Powell J. Patient perspectives on health advice posted on Internet discussion boards: a qualitative study. Health Expect. 2009;12:313–20.PubMedCrossRef
3.
go back to reference Lee C, Gray SW, Lewis N. Internet use leads cancer patients to be active health care consumers. Patient Educ Couns. 2010;81:S63–9.PubMedCrossRef Lee C, Gray SW, Lewis N. Internet use leads cancer patients to be active health care consumers. Patient Educ Couns. 2010;81:S63–9.PubMedCrossRef
5.
go back to reference Schröder S, Zöllner YF, Schaefer M. Drug related problems with antiparkinsonian agents: consumer Internet reports versus published data. Pharmacoepidemio Drug Saf. 2007;16:1161–6.CrossRef Schröder S, Zöllner YF, Schaefer M. Drug related problems with antiparkinsonian agents: consumer Internet reports versus published data. Pharmacoepidemio Drug Saf. 2007;16:1161–6.CrossRef
6.
go back to reference Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand. 2009;120:102–11.PubMedCrossRef Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand. 2009;120:102–11.PubMedCrossRef
9.
go back to reference Chee BW, Berlin R, Schatz B. Predicting adverse drug events from personal health messages. AMIA Annu Symp Proc. 2011;2011:217–26.PubMedCentralPubMed Chee BW, Berlin R, Schatz B. Predicting adverse drug events from personal health messages. AMIA Annu Symp Proc. 2011;2011:217–26.PubMedCentralPubMed
10.
go back to reference Schultz P, Stava C, Beck M, et al. Internet message board use by patients with cancer and their families. Clin J Oncol Nurs. 2003;7:663–7.PubMedCrossRef Schultz P, Stava C, Beck M, et al. Internet message board use by patients with cancer and their families. Clin J Oncol Nurs. 2003;7:663–7.PubMedCrossRef
11.
go back to reference Nagler RH, Gray SW, Romantan A, et al. Differences in information seeking among breast, prostate, and colorectal cancer patients: results from a population-based survey. Patient Educ Couns. 2010;81:S54–62.PubMedCrossRef Nagler RH, Gray SW, Romantan A, et al. Differences in information seeking among breast, prostate, and colorectal cancer patients: results from a population-based survey. Patient Educ Couns. 2010;81:S54–62.PubMedCrossRef
12.
go back to reference Mao JJ, Chung A, Benton A, et al. Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol Drug Saf. 2013;22:256–62.PubMedCrossRef Mao JJ, Chung A, Benton A, et al. Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol Drug Saf. 2013;22:256–62.PubMedCrossRef
13.
go back to reference Benton A, Ungar L, Hill S, et al. Identifying potential adverse effects using the web: a new approach to medical hypothesis generation. J Biomed Inform. 2011;44:989–96.PubMed Benton A, Ungar L, Hill S, et al. Identifying potential adverse effects using the web: a new approach to medical hypothesis generation. J Biomed Inform. 2011;44:989–96.PubMed
14.
15.
go back to reference Faye E, Bondon-Guitton E, Olivier-Abbal P, Montastruc JL. Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors. Eur J Clin Pharmacol. 2013;69:1819–26.PubMedCrossRef Faye E, Bondon-Guitton E, Olivier-Abbal P, Montastruc JL. Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors. Eur J Clin Pharmacol. 2013;69:1819–26.PubMedCrossRef
16.
go back to reference Haramburu F, Miremont-Salamé G, Bénard A, et al. Incidence of hospital admissions due to adverse drug reactions: the EMIR study. Fundam Clin Pharmacol. 2008;22(Suppl 1):20. Haramburu F, Miremont-Salamé G, Bénard A, et al. Incidence of hospital admissions due to adverse drug reactions: the EMIR study. Fundam Clin Pharmacol. 2008;22(Suppl 1):20.
18.
go back to reference Bégaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs: actualization of the method used in France. Therapie. 1985;40:111–8.PubMed Bégaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs: actualization of the method used in France. Therapie. 1985;40:111–8.PubMed
20.
go back to reference Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109–17.PubMedCrossRef Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109–17.PubMedCrossRef
21.
go back to reference Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.PubMedCrossRef Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.PubMedCrossRef
22.
go back to reference Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–9.PubMedCrossRef Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–9.PubMedCrossRef
24.
go back to reference Moore N, Noblet C, Kreft-Jais C, et al. French pharmacovigilance database system: examples of utilisation. Therapie. 1995;50:557–62.PubMed Moore N, Noblet C, Kreft-Jais C, et al. French pharmacovigilance database system: examples of utilisation. Therapie. 1995;50:557–62.PubMed
25.
go back to reference Buetow S, Henshaw J, Cha R, et al. Distinguishing objective from subjective assessments of the severity of medication-related safety events among people with Parkinson’s disease: a qualitative study. J Clin Pharm Ther. 2012;37:436–40.PubMedCrossRef Buetow S, Henshaw J, Cha R, et al. Distinguishing objective from subjective assessments of the severity of medication-related safety events among people with Parkinson’s disease: a qualitative study. J Clin Pharm Ther. 2012;37:436–40.PubMedCrossRef
26.
go back to reference Somers A, Petrovic M, Robays H, et al. Reporting adverse drug reactions on a geriatric ward: a pilot project. Eur J Clin Pharmacol. 2003;58:707–14.PubMed Somers A, Petrovic M, Robays H, et al. Reporting adverse drug reactions on a geriatric ward: a pilot project. Eur J Clin Pharmacol. 2003;58:707–14.PubMed
27.
go back to reference Sacilotto K, Bagheri H, Lapeyre-Mestre M, et al. Adverse drug effects notifications by nurses and comparison with cases reported by physicians. Therapie. 1995;50:455–8.PubMed Sacilotto K, Bagheri H, Lapeyre-Mestre M, et al. Adverse drug effects notifications by nurses and comparison with cases reported by physicians. Therapie. 1995;50:455–8.PubMed
28.
go back to reference Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011;24:386–95.PubMedCrossRef Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011;24:386–95.PubMedCrossRef
29.
go back to reference Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007;25:3797–9.PubMedCrossRef Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007;25:3797–9.PubMedCrossRef
30.
go back to reference Fontein DBY, Nortier JWR, Liefers GJ, et al. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy: results from the IDEAL randomized trial. Eur J Surg Oncol. 2012;38:110–7.PubMedCrossRef Fontein DBY, Nortier JWR, Liefers GJ, et al. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy: results from the IDEAL randomized trial. Eur J Surg Oncol. 2012;38:110–7.PubMedCrossRef
31.
go back to reference Hughes S, Cohen D. Can online consumers contribute to drug knowledge? A mixed methods comparison of consumer-generated and professionally controlled psychotropic medication information on the internet. J Med Internet Res. 2011;13:e53.PubMedCentralPubMedCrossRef Hughes S, Cohen D. Can online consumers contribute to drug knowledge? A mixed methods comparison of consumer-generated and professionally controlled psychotropic medication information on the internet. J Med Internet Res. 2011;13:e53.PubMedCentralPubMedCrossRef
32.
go back to reference Hazell L, Cornelius V, Hannaford P, et al. How do patients contribute to signal detection? A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK’s Yellow Card Scheme. Drug Saf. 2013;36:199–206.PubMedCrossRef Hazell L, Cornelius V, Hannaford P, et al. How do patients contribute to signal detection? A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK’s Yellow Card Scheme. Drug Saf. 2013;36:199–206.PubMedCrossRef
33.
go back to reference Blenkinsopp A, Wilkie P, Wang M, et al. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63:148–56.PubMedCentralPubMedCrossRef Blenkinsopp A, Wilkie P, Wang M, et al. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63:148–56.PubMedCentralPubMedCrossRef
34.
go back to reference MBongue TB, Sommet A, Pathak A. “Medicamentation” of society, non-disease and non-medications: a point of view from social pharmacology. Eur J Clin Pharmacol. 2005;61:309–13.PubMedCrossRef MBongue TB, Sommet A, Pathak A. “Medicamentation” of society, non-disease and non-medications: a point of view from social pharmacology. Eur J Clin Pharmacol. 2005;61:309–13.PubMedCrossRef
35.
go back to reference Aboutaam M. Analysis of patients’ narratives posted on social media websites on benfluorex (Mediator®) withdrawal in France. J Clin Pharm Ther. 2014;39:53–5.CrossRef Aboutaam M. Analysis of patients’ narratives posted on social media websites on benfluorex (Mediator®) withdrawal in France. J Clin Pharm Ther. 2014;39:53–5.CrossRef
36.
go back to reference Jarernsiripornkul N, Krska J, Capps PA, et al. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol. 2002;53:318–25.PubMedCentralPubMedCrossRef Jarernsiripornkul N, Krska J, Capps PA, et al. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol. 2002;53:318–25.PubMedCentralPubMedCrossRef
Metadata
Title
Undesirable Effects Related to Oral Antineoplastic Drugs: Comparison Between Patients’ Internet Narratives and a National Pharmacovigilance Database
Authors
Arnaud Pages
Emmanuelle Bondon-Guitton
Jean Louis Montastruc
Haleh Bagheri
Publication date
01-08-2014
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 8/2014
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-014-0203-6

Other articles of this Issue 8/2014

Drug Safety 8/2014 Go to the issue